+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Dasatinib-induced pulmonary arterial hypertension



Dasatinib-induced pulmonary arterial hypertension



British Journal of Clinical Pharmacology 84(5): 835-845



Drug-induced (group 1) pulmonary hypertension (PH) is an important subgroup of PH involving dasatinib as a likely related agent, which is a second-generation tyrosine kinase inhibitor (TKI) used in the treatment of chronic myeloid leukaemia (CML). The mechanism of dasatinib-induced pulmonary arterial hypertension (PAH) is unclear. However, the occurrence of PAH with late onset in CML patients suggests a chronic pathological mechanism with an insidious onset rather than an acute inflammatory or cardiac aetiology. Dasatinib has a broader effect than other TKIs; the major known difference between dasatinib and other TKIs is the additional inhibition of Src family kinases. Therefore, Src inhibition was thought to play a role in the development of dasatinib-induced PAH. However, recently, it was also speculated that chronic dasatinib therapy may cause pulmonary endothelial damage, attenuate hypoxic pulmonary vasoconstriction responses and increase susceptibility to PAH independently of the Src family kinase-induced mechanism. Dasatinib-induced PAH usually seems to be reversible with the cessation of the drug, and sometimes with PAH-specific treatment strategies. Transthoracic echocardiography can be recommended as a routine screening prior to dasatinib initiation, and this non-invasive procedure can be utilized in patients having signs and symptoms attributable to PAH during dasatinib treatment.

(PDF emailed within 0-6 h: $19.90)

Accession: 057523077

Download citation: RISBibTeXText

PMID: 29334406

DOI: 10.1111/bcp.13508


Related references

First histopathological evidence of irreversible pulmonary vascular disease in dasatinib-induced pulmonary arterial hypertension. European Respiratory Journal 51(3), 2018

Dasatinib-induced pulmonary arterial hypertension unresponsive to PDE-5 inhibition. European Respiratory Journal 42(3): 869-870, 2014

Dasatinib-induced pulmonary arterial hypertension - A rare late complication. Journal of Oncology Pharmacy Practice 2018: 1078155217753740, 2018

Computed tomography-measured pulmonary artery to aorta ratio and EUTOS score for detecting dasatinib-induced pulmonary arterial hypertension. International Journal of Cardiovascular Imaging 2019, 2019

Dasatinib-induced pulmonary arterial hypertension complicated with scleroderma: a case report. European Heart Journal. Case Reports 3(1): Ytz025, 2019

Dasatinib-Induced Pulmonary Arterial Hypertension Treated with Upfront Combination Therapy. Case Reports in Cardiology 2018: 3895197, 2018

Long-term outcomes of dasatinib-induced pulmonary arterial hypertension: a population-based study. European Respiratory Journal 50(1), 2018

Combination targeted pulmonary hypertension therapy in the resolution of Dasatinib-associated pulmonary arterial hypertension. Pulmonary Circulation 7(4): 803-807, 2017

Dasatinib: pulmonary arterial hypertension. French data. Prescrire International 20(120): 241-241, 2011

Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 125(17): 2128-2137, 2012

Reversible dasatinib-related pulmonary arterial hypertension in a CML patient. Japanese Journal of Clinical Hematology 57(5): 618-623, 2016

Clinical features of pulmonary arterial hypertension in patients receiving dasatinib. American Journal of Hematology 90(11): 1060-1064, 2016

Reversible Pulmonary Arterial Hypertension Associated with Dasatinib for Chronic Myeloid Leukemia. Cancer Research and Treatment 47(4): 937-942, 2017

Pulmonary arterial hypertension in a patient treated with dasatinib: a case report. Journal of Medical Case Reports 11(1): 362, 2018

Pulmonary Arterial Reactivity in Heart Failure with Preserved Ejection Fraction Induced Pulmonary Hypertension Similar to Pulmonary Arterial Hypertension. Journal of Cardiac Failure 19(8): S3-S4, 2013